for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Company News

BRIEF-CRITICAL OUTCOME TECHNOLOGIES DOSES FIRST PATIENT IN HNSCC ARM OF PHASE 1 TRIAL OF COTI-2

Oct 11 (Reuters) - Critical Outcome Technologies Inc :

* CRITICAL OUTCOME TECHNOLOGIES ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 TRIAL OF COTI-2 IN HEAD AND NECK SQUAMOUS CELL CARCINOMA

* CRITICAL OUTCOME TECHNOLOGIES - TOP-LINE DATA OF COTI-2 IN HEAD AND NECK SQUAMOUS CELL CARCINOMA EXPECTED IN 2018

* CRITICAL OUTCOME TECHNOLOGIES INC - REMAIN ON TRACK TO ANNOUNCE SECONDARY AND EXPLORATORY ENDPOINT DATA OF COTI-2 BY YEAR-END Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up